A 28-year-old man with mild persistent asthma has been on inhaled fluticasone propionate 100 mcg twice daily for 6 weeks. He reports good adherence with a spacer. However, he still experiences symptoms 3 times per week and one nocturnal awakening per week. Spirometry shows FEV₁ 82% predicted. What is the most appropriate next step in management?

Explanation

## Clinical Assessment This patient has **inadequate control on low-dose ICS monotherapy** after 6 weeks of adherent therapy. His symptom frequency (3×/week) and one nocturnal awakening/week classify him as **partially controlled** on Step 2 therapy. The appropriate next step per current GINA guidelines is **Step 3: Add a LABA to the existing ICS dose**. ## GINA Step-Care Escalation (2023 Update) | Step | Therapy | Indication | |---|---|---| | Step 1 | As-needed low-dose ICS-formoterol | Mild intermittent | | Step 2 | Low-dose ICS (maintenance) | Mild persistent | | **Step 3** | **Low-dose ICS + LABA** | **Partially controlled on Step 2** | | Step 4 | Medium/high-dose ICS + LABA | Uncontrolled on Step 3 | | Step 5 | Add-on therapy (LAMA, biologics) | Severe uncontrolled | **Key Point (GINA 2023):** For patients with mild persistent asthma who remain uncontrolled on low-dose ICS, the preferred Step 3 escalation is **addition of a LABA** (forming an ICS/LABA combination), NOT increasing the ICS dose. The dose-response curve for ICS is relatively flat above low doses — doubling the ICS dose provides only ~5% additional bronchodilation, whereas adding a LABA provides synergistic benefit through complementary mechanisms (β₂-receptor upregulation + anti-inflammatory effect). **High-Yield:** GINA explicitly states that ICS + LABA is **preferred over increasing ICS dose** at Step 3. This is supported by landmark trials (FACET, OPTIMA) showing ICS/LABA superiority over doubling ICS dose for symptom control and exacerbation reduction. ## Why Not the Other Options? - **Option A (Switch ICS class):** Switching between ICS molecules (fluticasone → beclomethasone) is not a recommended escalation strategy; all low-dose ICS have comparable efficacy at equivalent doses. - **Option C (Discontinue ICS, start LTRA monotherapy):** LTRA monotherapy is inferior to ICS monotherapy; discontinuing ICS in a partially controlled patient is inappropriate and potentially dangerous. - **Option D (Increase ICS to medium dose):** While historically taught, current GINA 2023 guidelines prefer ICS + LABA over ICS dose escalation at Step 3 due to superior efficacy and the flat ICS dose-response curve above low doses. ## Clinical Pearl Per **GINA 2023 (Global Initiative for Asthma)** and supported by **Harrison's Principles of Internal Medicine (21st ed.)**: The preferred Step 3 therapy is a **low-dose ICS/LABA combination inhaler** (e.g., fluticasone/salmeterol, budesonide/formoterol). This approach provides better symptom control, reduces exacerbations, and avoids unnecessary escalation of ICS-related systemic side effects. **Reassessment:** After initiating ICS + LABA, reassess in **4–6 weeks** to confirm adequate control before considering further escalation.